Clinically, although a consensus regarding the prognosis of WT1 expression level in newly diagnosed acute leukemia is still lacking, the WT1 expression has been successfully used as a marker of minimal residual disease, reliably predicting relapse after (induction of) chemotherapy or after hematopoietic stem cell transplantation [34,35,36]. This evidence concerns the gene WT1 and acute leukemia.